All lobbying filings

WHITMER & WORRALL, LLC

Lobbying for CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Coalition to promote lowering prescription drug prices.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 21, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 2

MARTIN WHITMER

Previously held: Deputy CoS-USDOT
ERIK KOMENDANT

Previously held: Legislative Correspondent, Rep. Zoe Lofgren (CA); Legislative Director, Rep. Jason Altmire (PA); Policy Director, Blue Dog Coalition

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 27

HR 3789
DTC Act of 2025
S 229
DTC Act of 2025
S 1041
Affordable Prescriptions for Patients Act
HR 4570
Interagency Patent Coordination and Improvement Act of 2025
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 2658
Medication Affordability and Patent Integrity Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
HR 3160
PREVAIL Act
S 1533
A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physic…
S 1546
Patent Eligibility Restoration Act of 2025
HR 3152
Patent Eligibility Restoration Act of 2025
HR 6485
Skinny Labels, Big Savings Act
S 43
Skinny Labels, Big Savings Act
S 1040
Drug Competition Enhancement Act
HR 3269
ETHIC Act
S 2276
ETHIC Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act
S 1095
Stop STALLING Act
S 3014
Ensuring Timely Access to Generics Act of 2025
S 1414
Expedited Access to Biosimilars Act
S 1032
Major Richard Star Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 2630
Saving NSF’s Workforce Act
HR 1262
Mikaela Naylon Give Kids a Chance Act
S 1785
No Handouts for Drug Advertisements Act
HR 3010
No Handouts for Drug Advertisements Act

Lobbying activity 4

Medicare/Medicaid

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

Pharmacy

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

Taxation/Internal Revenue Code

S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.